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Abstract: Hypercholesterolemia and statins are risk factors for aortic stenosis (AS) and vascular
calcification, respectively. Whether heterozygous subjects with familial hypercholesterolemia (HeFH)
treated with statins are at risk of AS is unknown. We study the prevalence of AS, aortic valve
calcification (AoVC), and aortic sclerosis (ASc) in elderly subjects with HeFH in a prolonged statin
treatment. Case-control study, cases were adults ≥65 years of age with a genetic diagnosis of HeFH,
LDLc >220 mg/dl, and statin treatment ≥5 years. Controls were relatives of HeFH patients, with
LDLc <190 mg/dl. Participants underwent a cardiac ultrasound for aortic valve analysis. We studied
205 subjects, 112 HeFH and 93 controls, with mean age 71.8(6.5) years and 70.0(7.3) years, respectively.
HeHF, with respect to controls, presented greater gradients of aortic transvalvular pressure, 7.4(7.3)
mmHg versus 5.0(2.8) mmHg, and maximum aortic velocity, 1.7(0.7) m/s versus 1.5(0.4) m/s, and
lower aortic valve opening area, 2.0(0.7) cm2 versus 2.4(0.6) cm2 (all p < 0.05). AoVC and ASc were
also more prevalent in HeFH (p < 0.05 between groups). Moderate/severe AS prevalence was higher
among HeFH: 7.1% versus 1.1% (age- and sex-adjusted odds ratio (OR) 8.33, p = 0.03). Independent
risk factors for aortic valve disease in HeFH were age and LDLc before treatment. The number
of years under statin treatment was not associated with any aortic valve measurement. Subjects
≥65 years with HeFH in prolonged statin treatment show more aortic valvular disease and higher
frequency of AS than controls. Life-long elevated LDLc exposure, rather than time of exposure to
statins, explains this higher risk.
Keywords: aortic stenosis; aortic sclerosis; heterozygous familial hypercholesterolemia; statins; aortic
valve calcification; LDL cholesterol
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1. Introduction
Familial hypercholesterolemia is a common autosomal codominant disease mostly caused by
mutations in the LDLR gene. The prevalence of heterozygous familial hypercholesterolemia (HeFH)
is approximately of 1/200–500 in most countries [1]. Patients with HeFH show very high plasma
concentration of low-density lipoprotein cholesterol (LDLc) [1–3] and, without lipid-lowering treatment,
approximately 50% of HeFH men and 30% of HeFH women will develop coronary heart disease
by the age of 50 years [1,4,5]. Fortunately, lipid-lowering treatment has decreased coronary heart
disease in HeFH, and many patients now have almost a normal life expectancy [5]. Other diseases
related to hypercholesterolemia, or to defects in the LDL receptor pathway, that are not reversed
by statins or that may go unnoticed with shorter life-spans may appear nowadays thanks to the
greater survival rate. This surge of new phenotypes has already been described in homozygous
familial hypercholesterolemia. In the latter condition, these pediatric patients used to die from
extremely premature coronary atherosclerosis. Given that the risk of coronary heart disease has been
substantially reduced thanks to starting LDL apheresis from childhood [6–8], when homozygous
familial hypercholesterolemia patients get older, they often show calcification of the aortic annulus
and ascending aorta and an increased risk of severe aortic stenosis (AS) [7]. AS is an inflammatory and
degenerative process caused by endothelial damage. The disease involves lipid infiltration, progressive
fibrosis, and calcification, and ends up narrowing the aortic valve area [9]. Interestingly, AS prevalence
has increased steadily in recent years in most countries, including Spain [10]. Risk factors for AS
include age, hypercholesterolemia, diabetes mellitus, and hypertension, which are also traditional
risk factors for arteriosclerosis [11]. Unfortunately, treatment for hypercholesterolemia with statins
and ezetimibe has not proven to reduce AS progression in the long-term, although some benefit was
observed only in a subset of patients with mild AS and high pretreatment LDLc levels [12,13]. Several
factors may predispose HeFH patients to AS. They usually have very high LDLc concentration from
childhood, a known risk factor for AS. In addition, chronic treatment with statins favors vascular
calcification, which occurs when the lipidic and inflammatory components of the atheroma plaques
are reduced by these drugs [14]. Besides, many HeFH patients have elevated lipoprotein(a) (Lp(a))
concentration, another well-known independent risk factor for vascular and aortic valve calcification
(AoVC) [15,16]. Success of current treatment for HeFH may have allowed that these factors combine
with the effects of aging. Nearly half of the elderly general population (>75 years old) have AoVC
to some extent, and a fraction of them suffer AS [15]. Consequently, previous high early coronary
heart disease (CHD) mortality in HeFH [17] could have hidden AoVC and AS that tend to appear at
older ages. LDLR mutations strongly predict AoVC [18], but whether elderly HeFH patients are at
higher risk of AS is still unknown. We hypothesized that many subjects with HeFH under chronic
treatment with statins have not only AoVC, but also impaired hemodynamic parameters of the aortic
valve function, even reaching AS diagnostic criteria. We aimed to study these functional differences
by comparing HeFH patients with controls, to assess, in addition, the current prevalence of AS in
HeFH subjects ≥65 years in chronic treatment with statins, and to explore potential risk factors for the
development of AS in HeFH.
2. Methods
2.1. Study Characteristics
This is an observational, multicenter, case-control study. Five lipid clinics throughout Spain took
part in the study. Consecutive HeFH cases were recruited with the following criteria: Age ≥65 years; a
pathogenic mutation in a candidate gene for familial hypercholesterolemia (LDLR, APOB, or PCSK9) in
the subject or in a first-degree relative; historic LDLc levels ≥220 mg/dl without lipid-lowering therapy;
and statin treatment ≥5 years in all cases. Controls were selected from relatives of HeFH patients from
the lipid clinics, requiring: Absence of hypercholesterolemia (LDLc <190 mg/dl without lipid-lowering
treatment); age ≥55 years; and being either HeFH partners who cohabited >25 years or HeFH siblings.
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Additional HeFH cases were recruited from relatives of cases when they fulfilled the inclusion criteria.
Participants were excluded if they had a personal history of rheumatic heart disease.
The key data collection component of the study was a transthoracic echocardiogram. Laboratory
data were obtained from records in the lipid clinics from dates as close as possible (<1 year) to the
cardiac ultrasound, if they were on stable lipid-lowering treatment. When these were not available, a
blood sample was drawn during the visit. All procedures were carried out locally, at each lipid clinic.
All subjects gave a written informed consent to the protocol, which was approved by a central
ethical committee (Comité Ético de Investigación Clínica de Aragón, CEICA).
2.2. Transthoracic Echocardiography
Transthoracic conventional echocardiograms were performed by cardiologists who were nationally
certified for echocardiography. Echocardiogram studies were focused on the aortic valve at the same
position for all patients. The following variables were measured: Mean aortic valve pressure gradient;
maximum aortic velocity (Vmax); aortic valve area; aortic valve area indexed to body surface area;
bicuspid or tricuspid aorta valve; valvular thickening >3 mm; and calcification of the aortic valve
leaflets. The cardiologists performing echocardiograms were blinded to the diagnosis of HeFH. Degree
of calcification of the aortic valve was scored as follows: 1, no calcification; 2, mildly calcified (small
isolated spots); 3, moderately calcified (multiple larger spots); and 4, heavily calcified (extensive
thickening and calcification of all cusps) [19]. AS was diagnosed as defined by the American College
of Cardiology/American Heart Association Task Force on Practice Guidelines [11]. AS is considered
present with any of the following findings: Mean aortic valve pressure gradient ≥20 mm; Vmax ≥2 m/s;
and aortic valve area ≤1 cm2. Identified AS stages were mild (Vmax 2–2.9 m/s, valve pressure gradient
<20 mm, and aortic valve area >1cm2); moderate (Vmax 3-3.9 m/s or valve pressure gradient 20–39 mm
and aortic valve area >1 cm2), and severe (Vmax ≥4 m/s, valve pressure gradient ≥40 mm, or aortic
valve area ≤1 cm2) [11]. Aortic valve sclerosis (ASc), a milder aortic condition, was defined in the
presence of thickening (>3 mm) and/or calcification of the aortic valve without significant obstruction
of flow (Vmax <2 m/s) or AS criteria [20].
2.3. Clinical Interview
Within clinical data information, we collected age, gender, level of education, history of smoking,
hypertension, diabetes, personal history of cardiovascular disease and familial history of cardiovascular
disease in first-degree relatives, age at which cardiovascular events occurred, lipid values without
treatment, and history of lipid-lowering treatment. Level of education was classified as primary school,
secondary school, and higher education. Current smoking was defined by smoking in the present or
having smoked in the last year. Former smokers were defined as subjects having smoked at least 50
cigarettes in their lifetime, but not having smoked in the last year. Smoking burden was recorded as
the number of daily packets smoked multiplied by the number of years smoked.
About the lipid-lowering treatment, we recorded age at which statin treatment began, statin most
commonly prescribed, statin dose, ezetimibe use, age at which ezetimibe treatment began, and which
statin and dose are prescribed as current treatment.
In participants with previous cardiovascular disease, age of first event and kind of event was
recorded: Myocardial infarction; acute coronary syndrome requiring hospitalization; ischemic stroke;
coronary, carotid, or peripheral revascularization; recovered sudden death; or aortic aneurysm.
2.4. Physical Exam
In the physical exam, we recorded height, weight, systolic and diastolic blood pressure, and
presence of tendon xanthomas. Body mass index (BMI) was calculated as weight in kilograms divided
by the square of height in meters.
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2.5. Laboratory Tests
When current lipid values (<1 year) were not available, then a blood sample was obtained to
determine cholesterol, triglycerides, HDLc, apolipoprotein B (apo B), Lp(a), glucose, and HbA1c.
Laboratory measurements and sample preservation were performed at each center.
2.6. Definitions
Arterial hypertension was defined as systolic blood pressure≥140 mm Hg, diastolic blood pressure
≥90 mm Hg, or current use of antihypertensive medication. Diabetes was defined as fasting plasma
glucose ≥126 mg/dl, HbA1c ≥6.5%, or current use of antidiabetic medication.
2.7. Statistical Analysis
Summary data are expressed as mean (standard deviation) or percentage. For comparisons
between cases and controls, aortic valve ultrasound variables and presence of aortic valve affectation
levels are modeled in linear and logistic regressions based on generalized estimating equations (GEE)
with exchangeable variance structure (to account for family links) with different levels of adjustment:
Unadjusted, adjusted for sex and age, and additionally adjusted for untreated LDLc concentration.
Analyses stratified by cases and controls and those restricted to cases were based on generalized
linear models, and they included, in order to estimate their influence, the variable untreated LDLc
concentration or years of life treated with lipid-lowering drugs. Influence of LDLc and lipid-lowering
treatment were studied separately in cases and controls strata. All of the analyses were performed
with the statistical software R version 3.4.4. and the package “gee” version 4.13.19.
3. Results
The research team recruited 205 subjects, 112 cases and 93 controls. Mean age was 71.8 years and
70.0 years in the case and control groups, respectively. Besides untreated total and LDLc, age, previous
cardiovascular disease prevalence, and family history of premature cardiovascular disease prevalence
were also higher in the HeFH group than in the control group. BMI was similar in both groups. There
were no differences in smoking, hypertension, or type 2 diabetes mellitus (Table 1). All cases were
on lipid-lowering treatment with a mean treatment time of 22.5 (8.7) years. No case or control had a
history of aortic valve replacement.
3.1. Aortic Valve Characterization
Mean aortic valve pressure gradient was higher in cases (7.4 mmHg) than in controls (5.0 mmHg),
after adjusting for age and sex (p = 0.002). HeFH patients, compared with controls, had greater
maximum aortic velocity (Vmax) (1.7 m/s and 1.5 m/s, respectively, p = 0.011), and lower aortic valve
area (2.0 cm2 and 2.4 cm2, respectively, p < 0.001). Among HeFH patients, average valvular calcification
score of the aortic valve leaflets was higher and valvular thickening was more prevalent (p = 0.004). Left
ventricular ejection fraction tended to be lower in cases (65.7% vs. 67.2%, p = 0.056). All studied valves
were tricuspid. AS with moderate or severe criteria and ASc were more prevalent among HeFH (7%
vs. 1%, age- and sex-adjusted OR 8.33, 95% confidence interval (CI) 1.22, 57.10, p = 0.031; and 55% vs.
32%, age- and sex-adjusted OR 1.90, 95% CI 1.04, 3.47, p = 0.061, respectively) (Table 2) and increased
with age (Figure 1). Additionally, adjusting these comparisons of aortic measurements and stenosis
prevalence for untreated LDLc concentrations rendered all differences non-significant. Thus, LDLc
could justify a considerable amount of the valve differences between HeFH and controls, but LDLc is
part of the definition of case and control, and stratified regressions were performed to clarify the issue.
They showed that age, but not LDLc, was significantly associated with all aortic valve variables among
controls, but Vmax and aortic valve calcification scores were also associated with untreated LDLc
concentration among HeFH cases (Supplementary Table S1). Mean aortic valve gradient increased
4.1 (2.1, 6.1) mmHg/10 year among cases, while it only increased 0.8 (0.0, 1.6) mmHg/10 year among
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controls across different age groups (Supplementary Table S1 and Figure 2). All clinical and laboratory
data were similar in all aortic valve stages except for the presence of tendon xanthomas (Supplementary
Table S2).
3.2. Risk Factors for Valvular Disease
In order to evaluate how statin treatment could modify aortic valve parameters in HeFH patients,
we used models including sex, age, and length of statin treatment among HeFH patients. Aortic
valve area decreased, and aortic valve calcification score increased significantly with age (p < 0.001),
independently of statins (Table 3). Ejection fraction was independent of age but decreased with length
of statin treatment (p = 0.005). Mean aortic valve gradient increased with age in cases and controls, but
with higher incremental rate in HeFH (Figure 2).
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Table 1. Baseline clinical and laboratory characteristics of cases and controls.
Mean (SD) / proportion (n = count) Controls Cases
n Mean/% n Mean/% p-value
Age (years) 93 70.0 (7.3) 112 71.8 (6.5) 0.038
Sex, women % (n = count) 93 51.6 (n = 48) 112 66.1 (n = 74) 0.050
Weight (Kg) 92 75.9 (14.3) 110 72.1 (13.5) 0.054
Height (cm) 92 161.7 (8.5) 110 159.4 (9.9) 0.075
Systolic blood pressure (mmHg) 92 136.7 (14.9) 110 134.1 (16.9) 0.199
Diastolic blood pressure (mmHg) 92 79.5 (9.7) 110 77.1 (9.7) 0.089
Body mass index (Kg/m2) 92 29.0 (4.7) 110 28.3 (4.0) 0.265
Tendon xanthomas, % (n = count) 93 0.0 (n = 0) 102 39.2 (n = 40) <0.001
Hypertension, % (n = count) 93 55.9 (n = 52) 112 54.5 (n = 61) 0.769
Type 2 diabetes, % (n = count) 93 14.0 (n = 13) 112 21.4 (n = 24) 0.139
Previous cardiovascular disease, % (n = count) 93 16.1 (n = 15) 112 27.7 (n = 31) 0.036
Family history of premature cardiovascular
disease, % (n = count) 89 25.8 (n = 23) 100 45.0 (n = 45) <0.001
Packages/day × number of years smoking 90 15.2 (25.3) 108 9.8 (21.6) 0.120
Lipid-lowering treatment, % (n = count) 93 51.6 (n = 48) 112 100.0 (n = 112) <0.001
Statin treatment (years) 48 8.3 (7.2) 110 22.5 (8.7) <0.001
Ezetimibe treatment, % (n = count) 68 8.8 (n = 6) 112 83.0 (n = 93) <0.001
Untreated total cholesterol (mg/dL) 93 223.8 (43.3) 111 395.9 (73.0) <0.001
Untreated triglycerides (mg/dL) 93 145.7 (119.0) 112 139.7 (76.3) 0.669
Untreated HDLc (mg/dL) 91 56.9 (15.3) 112 55.7 (13.6) 0.621
Untreated LDLc (mg/dL) 90 138.0 (31.7) 111 314.2 (71.4) <0.001
Continuous data are expressed as mean (standard deviation, SD); categorical data are expressed as percentages (n = count). HDLc: High-density lipoprotein cholesterol; LDLc: Low-density
lipoprotein cholesterol. p-values from linear and logistic regressions based on generalized estimating equations (GEE) with exchangeable variance structure, unadjusted.
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Table 2. Morphological and hemodynamic parameters of aortic valve in cases and controls.
Mean (SD)/proportion (n = count) Controls Cases
n mean/% n mean/% p-value * p-value ** p-value ***
Mean aortic valve pressure gradient (mm) 92 5.0 (2.8) 111 7.4 (7.3) 0.002 0.003 0.626
Maximum aortic velocity (Vmax) (m/s) 92 1.5 (0.4) 111 1.7 (0.7) 0.004 0.011 0.959
Aortic valve area (cm2) 92 2.4 (0.6) 107 2.0 (0.7) <0.001 <0.001 0.771
Left ventricular ejection fraction (%) 93 67.2 (7.0) 111 65.7 (9.5) 0.167 0.056 0.285
Aortic valve velocity ratio 61 0.73 (0.11) 61 0.70 (0.14) 0.244 0.138 0.321
Calcification of the aortic valve leaflets (score) 92 0.7 (0.9) 110 1.1 (1.0) 0.002 0.008 0.723
Valvular thickening >3 mm, % (n = count) 93 12.9 (n = 12) 112 27.7 (n = 31) 0.006 0.004 0.600
Aortic stenosis, % (n = count) 93 11.8 (n = 11) 112 20.5 (n = 23) 0.107 0.171 0.842
Aortic stenosis moderate or severe, % (n = count) 93 1.1 (n = 1) 112 7.1 (n = 8) 0.067 0.031 0.187
Aortic sclerosis, % (n = count) 92 34.8 (n = 32) 111 49.5 (n = 55) 0.046 0.061 0.337
Continuous data are expressed as mean (SD); categorical data are expressed as percentages (n = count). p-values from linear and logistic regressions based on generalized estimating
equations (GEE) with exchangeable variance structure. p- value *: Unadjusted; p -value **: Adjusted for sex and age; p-value ***: Adjusted for sex, age, and untreated LDLc concentration.
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Table 3. Influence of age and length of lipid-lowering treatment on aortic valve characteristics in HeFH.
Morphological and hemodynamic parameters Cases
Per each 10 year of age
Difference/OR (95% CI) p-value
Per each 10 year of lipid-lowering
use Difference/OR (95% CI) p-value
Mean aortic valve pressure gradient (mm) 4.623 (2.518, 6.728) <0.001 0.214 (−1.304, 1.732) 0.783
Maximum aortic velocity (Vmax) (m/s) 0.394 (0.185, 0.603) <0.001 0.012 (−0.139, 0.162) 0.881
Aortic valve area (cm2) −0.373 (−0.562, −0.185) <0.001 0.001 (−0.133, 0.135) 0.990
Left ventricular ejection fraction (%) −1.924 (−4.634, 0.787) 0.167 −2.877 (−4.827, −0.927) 0.005
Calcification of the aortic valve leaflets (score) 0.698 (0.418, 0.979) <0.001 −0.034 (−0.233, 0.165) 0.737
Valvular thickening >3 mm, OR 1.36 (0.69, 2.63) 0.359 0.86 (0.52, 1.41) 0.549
Aortic stenosis, OR 2.11 (1.04, 4.37) 0.038 0.94 (0.52, 1.65) 0.817
Aortic stenosis moderate or severe, OR 2.95 (1.07, 8.26) 0.032 0.82 (0.29, 2.15) 0.687
Aortic sclerosis, OR 1.23 (0.67, 2.32) 0.510 1.03 (0.66, 1.62) 0.883
Linear and logistic regressions based on generalized linear models (GLM). HeFH: heterozygous familial hypercholesterolemia; OR: odds ratio; CI: Confidence Interval. p-value from a
single model, adjusted for sex.
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4. Discussion
In the present study, we described the prevalence of aortic disease in HeFH patients ≥65 years
under long-term treatment with lipid-lowering drugs. Aortic valve involvement in HeFH has been
previously explored, but, to our knowledge, this is the first work focused on elderly subjects, the most
clinically relevant population due to the close relationship of AS with age, and the first to describe the
prevalence of AS and to evaluate the potential role of statin treatment in development of aortic disease
in HeFH. Our results are in agreement with those recently published from a registry-based prospective
cohort study in Norway, in which a marked increased risk of AS in HeFH was found compared with
the general Norwegian population [21].
4.1. Prevalence of AS in HeFH
In our study, AS prevalence is more than three times higher than that reported for this group of age
in the general population, 1.5–3%, and also higher than in our related control sample [22–25]. In view
of this substantially elevated prevalence, a systematic transthoracic echocardiography is probably
justified for the screening of AS in elderly HeFH over 65 years.
Several studies have previously analyzed aortic valve thickening or calcification in HeFH. Ten
Kake et al. compared a cohort of 59 HeFH subjects from the Netherlands with controls and showed
that the patients with HeFH, especially those with LDLR-negative mutations, showed higher AoVC
prevalence (41% versus 21%, respectively, p < 0.001) [18]. This ratio is similar to the one observed in our
study. However, the authors did not report data on AS, probably because their sample was smaller than
ours and it included younger patients. In the Cardiovascular Health Study, clinically defined familial
hypercholesterolemia was associated with AoVC and ASc, but an association with AS could not be
demonstrated [26,27]. In our study, in addition to fulfilling clinical lipidic criteria, all cases were defined
by having a genetic mutation in a gene that causes familial hypercholesterolemia, ascertained directly
in them or in a blood-relative. It is well established that familial hypercholesterolemia definition
based exclusively on clinical criteria includes other forms of genetic hypercholesteremia [28,29], and
hypercholesterolemic subjects with a genetic mutation have more severe cardiovascular phenotypes
than in the absence of mutation, even with a similar LDLc concentration at the moment of diagnosis [30].
4.2. Risk Factors for Aortic Valvular Disease
Our results support that atherosclerosis risks factors, including high LDLc throughout life, are
major risk factors for AS [31]. AS is probably produced by a combination of mechanical stress and
endothelial damage of the aortic valves, driving to subsequent valve inflammation, fibrosis, calcification,
and progressive valve narrowing [9]. Mechanical stress affects the endothelial function and facilitates
infiltration of lipids and inflammatory cells (T-cells) into the valve. All of these mechanisms are
involved in the inflammatory activity [32,33]. As a result, fibroblasts differentiate into myofibroblasts,
which, under the influence of angiotensin, promote thickening of the valve [9]. Hypercholesterolemia
treatment does not prevent progression from moderate to severe AS once AS is already established [34],
suggesting that hypercholesterolemia plays a role in the startup process but has little effect in the
advanced disease [35]. Our study would support current guidelines, which recommend early and
intensive treatment of HeFH to prevent not only coronary disease, but also valvular disease later in
life [5].
4.3. Statins and Valvular Disease
Lipid-lowering treatment is associated with increased vascular calcification [36] due, at least
in part, to statins-enhanced new bone formation in bone cells, via increased expression of gene
BMP-2 [37]. Furthermore, the reduction in inflammatory markers associated with statins is significantly
associated with the percentage of calcium volume within the coronary plaques [38]. Consequently, it
has been speculated that lipid-lowering treatment, especially prolonged statin treatment, may favor
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development of AoVC and AS [39]. Although, other studies such as Al Kindi’s showed that vascular
calcification associated to statins is not related to valve calcification [40]. Currently, HeFH are the
patients to whom earlier, more intense, and more prolonged lipid-lowering drugs are prescribed.
Hence, our elderly HeFH sample, exposed to statins for a mean of 22.5 years, is excellent to study this
potential association. We found that the number of years under statin treatment is not a risk factor
for AS, indicating that if there is any risk of AS with statin, it is highly compensated by the beneficial
effect on LDLc, as it has been previously suggested [22]. These results are in full agreement with those
found in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, where, in a non-prespecified
post-hoc analysis, lipid-lowering treatment impeded the progression of AS in patients with the highest
LDL cholesterol concentration ( >160 mg/dL) and mild AS at baseline [41]. Statin therapy was also
significantly associated with a lesser change in aortic valve area in SALTIRE and RAAVE trials [42].
4.4. Study Limitations
This was a multicenter project in which echocardiographic studies were performed by different
researchers, and thus a certain degree of variability may exist in the measurements. However, all
ultrasound scans were performed by cardiologists who were experts in echocardiography, with practice
within hospitals of the Spanish National Health System, and all of them certified at the national level
with homogeneous and strict criteria. In addition, echocardiographers were blinded to the diagnosis
of HeFH to avoid bias.
Measurements of aortic valve functionality may vary in the presence of abnormal systolic
function [43]. Although it was not an exclusion criterion, none of our cases and controls had left
ventricular ejection fraction (LVEF) <40% or hypertrophic cardiomyopathy, thus, this limitation does
not play an important role in our study, and all measurements of the valvular surface could be
performed by continuity equation, the best standardized procedure. Finally, some data on the personal
history of lipid-lowering drug use and family history of cardiovascular disease were self-reported by
the participants, and they may have been affected by some degree of recall inaccuracy. However, the
main outcome and the inclusion and exclusion criteria for the cases and controls groups were based on
objective data, collected or verified by the research team.
It would had been important to have the lifetime LDLc exposure to study the effect of cumulative
LDLc on AS. Considering that we are dealing with elderly patients, this is not feasible. However, we
considered LDLc at diagnosis and the number of years under statin treatment, and we believe that
both variables are good subrogates of lifetime LDLc exposure.
5. Conclusions.
Subjects ≥65 years with HeFH in prolonged statin treatment for a mean period of over 22 years
show more aortic valvular disease and higher frequency of AS than controls. Independent risk factors
for aortic valve disease in HeFH were age and LDLc before treatment. Duration of statin treatment
was not associated with any aortic valve measurement. Hence, cumulative LDLc exposure, rather than
time of exposure to statins, explains this higher risk. These results suggest that elderly HeFH should
be monitored for the presence of aortic disease, and emphasize the importance of early lipid-lowering
treatment in HeFH population to prevent not only coronary disease, but also aortic valvular disease.
Furthermore, our study provides additional support to the already established body of work on the
role of hypercholesterolemia on AS.
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